[go: up one dir, main page]

IN2012DN00791A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00791A
IN2012DN00791A IN791DEN2012A IN2012DN00791A IN 2012DN00791 A IN2012DN00791 A IN 2012DN00791A IN 791DEN2012 A IN791DEN2012 A IN 791DEN2012A IN 2012DN00791 A IN2012DN00791 A IN 2012DN00791A
Authority
IN
India
Prior art keywords
streptococcus pneumoniae
prophylactically
elderly
antigens
young
Prior art date
Application number
Inventor
Todd Gierahn
Richard Malley
Original Assignee
Genocea Biosciences Inc
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc, Childrens Medical Center filed Critical Genocea Biosciences Inc
Publication of IN2012DN00791A publication Critical patent/IN2012DN00791A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
IN791DEN2012 2009-06-29 2010-06-29 IN2012DN00791A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22154109P 2009-06-29 2009-06-29
US24061609P 2009-09-08 2009-09-08
US24059809P 2009-09-08 2009-09-08
US31626710P 2010-03-22 2010-03-22
PCT/US2010/040406 WO2011008548A1 (en) 2009-06-29 2010-06-29 Vaccines and compositions against streptococcus pneumoniae

Publications (1)

Publication Number Publication Date
IN2012DN00791A true IN2012DN00791A (en) 2015-06-26

Family

ID=43449681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN791DEN2012 IN2012DN00791A (en) 2009-06-29 2010-06-29

Country Status (15)

Country Link
US (2) US10105412B2 (en)
EP (1) EP2448592B1 (en)
JP (1) JP5931724B2 (en)
KR (1) KR101748453B1 (en)
CN (2) CN102548572A (en)
AU (1) AU2010273708B2 (en)
BR (1) BRPI1011919A2 (en)
CA (1) CA2803061A1 (en)
IL (1) IL217166A0 (en)
IN (1) IN2012DN00791A (en)
MX (1) MX2012000158A (en)
NZ (1) NZ597858A (en)
RU (1) RU2580299C2 (en)
SG (2) SG177402A1 (en)
WO (1) WO2011008548A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000158A (en) 2009-06-29 2012-06-08 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae.
EP3165531B1 (en) 2010-03-12 2020-11-25 Children's Medical Center Corporation Immunogenic composition, vaccine, and uses thereof
US8906389B2 (en) * 2010-12-21 2014-12-09 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Determination of the efficacy of an anti-mycobacterial vaccination
AU2012207088A1 (en) * 2011-01-20 2013-05-02 Children's Medical Center Corporation Vaccines and compositions against Streptococcus pneumoniae
TW201249824A (en) * 2011-03-09 2012-12-16 Glaxosmithkline Llc Peptide deformylase inhibitors
BR112013028887B1 (en) 2011-05-11 2020-10-06 Children's Medical Center Corporation IMMUNOGENIC COMPOSITION PRESENTING MULTIPLE ANTIGENS, AND METHODS AND USES OF THE SAME
AU2013209513B2 (en) * 2012-01-20 2017-10-05 Children's Medical Center Corporation Fused antigen vaccines and compositions against Streptococcus pneumoniae
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US20150079132A1 (en) * 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
EP3131579A4 (en) 2014-04-18 2017-10-25 The Children's Medical Center Corporation Vaccine adjuvant compositions
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR112019014833A2 (en) 2017-01-20 2020-04-14 Pfizer immunogenic compositions for use in pneumococcal vaccines
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110730670A (en) 2017-03-28 2020-01-24 儿童医疗中心有限公司 Multi-antigen presentation system (MAPS) -based staphylococcus aureus vaccines, immunogenic compositions, and uses thereof
US11612647B2 (en) 2017-06-23 2023-03-28 University Of Maryland, Baltimore Immunogenic compositions
EP3720488A1 (en) 2017-12-04 2020-10-14 Intervet International B.V. Vaccination with replicon particles and oil adjuvant
CA3111459A1 (en) 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
TWI852943B (en) 2018-09-12 2024-08-21 美商兒童醫療中心公司 Pneumococcal fusion protein vaccines
RU2728938C1 (en) * 2020-05-06 2020-08-03 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) Use of dalargin for production of drug preparations for preventing pneumonia
WO2022013160A1 (en) 2020-07-16 2022-01-20 Henriques Normark Birgitta Streptococcal vaccines
IL311239A (en) 2021-09-09 2024-05-01 Affinivax Inc Multivalent pneumococcal vaccines

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
JP2000511769A (en) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション New compound
US6420135B1 (en) 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
EP1002090A2 (en) 1997-05-06 2000-05-24 Human Genome Sciences, Inc. $i(ENTEROCOCCUS FAECALIS) POLYNUCLEOTIDES AND POLYPEPTIDES
CA2304925A1 (en) 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Borrelia burgdorferi polynucleotides and sequences
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5882885A (en) * 1997-07-17 1999-03-16 Smithkline Beecham Corporation Glycogen phosphorylase
US5994101A (en) * 1997-07-18 1999-11-30 Smithkline Beecham Corporation DNA encoding gidA1 polypeptides
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
CN1318103A (en) 1998-07-27 2001-10-17 微生物技术有限公司 Nucleic acids and proteins from streptococcus pneumoniae
US6887480B1 (en) 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
EP1185297B1 (en) 1999-06-10 2006-05-10 MedImmune, Inc. Streptococcus pneumoniae proteins and vaccines
HUP0203880A2 (en) * 1999-12-23 2003-03-28 Vmax Limited Streptococcus pyogenes virulence genes and proteins and their use
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
CA2425303A1 (en) * 2000-10-27 2002-05-02 John Telford Nucleic acids and proteins from streptococcus groups a & b
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP2258842A1 (en) 2001-04-16 2010-12-08 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP2275127B1 (en) 2002-04-02 2012-09-19 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
US20090252756A1 (en) * 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
AU2003260102A1 (en) * 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
AU2003268353A1 (en) 2002-08-30 2004-03-19 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
EP1615950A2 (en) * 2003-04-15 2006-01-18 Intercell AG S. pneumoniae antigens
GB0318688D0 (en) * 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
EP1828231A2 (en) 2004-12-22 2007-09-05 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus
EP1855717A4 (en) 2005-02-11 2009-12-23 Ace Biosciences As Surface-located streptococcus pneumoniae polypeptides
US20110177960A1 (en) * 2006-03-10 2011-07-21 Ellen Murphy Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae
US20100015168A1 (en) * 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
WO2009011971A2 (en) 2007-05-18 2009-01-22 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health And Human Services, Centers For Disease Control And Prevention Primers and probes for the detection of streptococcus pneumoniae
EP2167531B1 (en) 2007-05-25 2012-03-21 Novartis AG Streptococcus pneumoniae pilus antigens
WO2008150885A1 (en) * 2007-05-29 2008-12-11 Board Of Regents, The University Of Texas System Modulation of the th-17 cell mediated immune responses
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20100278819A1 (en) * 2007-09-14 2010-11-04 Katholieke Universiteit Leuven Streptococcus pneumoniae vaccines
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
CA2717499A1 (en) * 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
CA2987102A1 (en) 2008-07-01 2010-01-07 Genocea Biosciences, Inc. Screening system
WO2010064243A1 (en) 2008-12-03 2010-06-10 Protea Vaccine Technologies Ltd. GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
US20120100172A1 (en) * 2009-06-25 2012-04-26 Michael Tal Immunogenic streptococcus pneumoniae peptides and peptide-multimers
MX2012000158A (en) 2009-06-29 2012-06-08 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae.
WO2011064781A1 (en) 2009-11-30 2011-06-03 Ben-Gurion University Of The Negev Research And Development Authority S. pneumoniae adhesins
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5065434B2 (en) * 2010-04-06 2012-10-31 株式会社日立製作所 Management method and management apparatus
WO2011128892A2 (en) 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
WO2011141968A1 (en) 2010-05-14 2011-11-17 Hitachi, Ltd. Storage apparatus and data retaining method for storage apparatus
AU2012207088A1 (en) * 2011-01-20 2013-05-02 Children's Medical Center Corporation Vaccines and compositions against Streptococcus pneumoniae

Also Published As

Publication number Publication date
JP5931724B2 (en) 2016-06-08
NZ597858A (en) 2014-01-31
EP2448592A4 (en) 2013-04-24
WO2011008548A1 (en) 2011-01-20
US20190298795A1 (en) 2019-10-03
RU2011153032A (en) 2013-08-10
KR20120093141A (en) 2012-08-22
IL217166A0 (en) 2012-02-29
CN102548572A (en) 2012-07-04
US10105412B2 (en) 2018-10-23
SG177402A1 (en) 2012-02-28
US11207375B2 (en) 2021-12-28
AU2010273708B2 (en) 2015-10-01
BRPI1011919A2 (en) 2017-09-26
RU2580299C2 (en) 2016-04-10
CN107126557A (en) 2017-09-05
AU2010273708A8 (en) 2012-06-14
EP2448592B1 (en) 2020-06-17
MX2012000158A (en) 2012-06-08
WO2011008548A8 (en) 2012-03-08
US20110020386A1 (en) 2011-01-27
EP2448592A1 (en) 2012-05-09
CA2803061A1 (en) 2011-01-20
JP2012532134A (en) 2012-12-13
KR101748453B1 (en) 2017-06-16
SG10201403702SA (en) 2014-09-26
AU2010273708A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
IN2012DN00791A (en)
MY163871A (en) Vaccines and compositions against streptococcus pneumoniae
IL219876A (en) Antibody or fragment thereof against human b7-h1, compositions comprising same and use thereof in the preparation of medicaments
MX2009009931A (en) Probiotics to reduce development of allergy in infants born by caesarean section.
SG10201607595WA (en) Novel conjugates, preparation thereof, and therapeutic use thereof
MX340830B (en) Pneumococcal vaccine and uses thereof.
IL216582A0 (en) Composition for use in decreasing the transmission of human pathogens, devices comprising the same and uses thereof
MX2016008226A (en) Prebiotic oral care methods using a saccharide.
MX2011007456A (en) Cna_b domain antigens in vaccines against gram positive bacteria.
WO2013109995A3 (en) Fused antigen vaccines and compositions against streptococcus pneumoniae
MX2016000099A (en) Synthetic vaccines against streptococcus pneumoniae type 1.
EP2547650A4 (en) HYDRATED AGOMÉLATINE BROMHYDRATE AND ITS PREPARATION
MX342832B (en) Treatment or prevention of infection.
WO2009115509A3 (en) Antigenic protein fragments of streptococcus pneumoniae
IL206438A0 (en) The vicky' nursing pillow
IL194353A0 (en) Lysobactin amides
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
PT2488158E (en) IMPROVED MEDICINAL FORMULATIONS IN THE FORM OF AEROSOL
UA105944C2 (en) Drug formulation with theobromine and decongestant for treatment of cough
TR200909786A1 (en) Effervescent tablet and granule formulation containing cefixime.
MX2010004734A (en) Novel antiretroviral combination.
WO2013074048A3 (en) Tablet forms comprising quetiapine fumarate
MY158116A (en) Combination vaccine against streptococcus
IT1395151B1 (en) DEVICE TO FIND THE PRESENCE OF NON-SELF-SUFFICIENT PEOPLE OR CHILDREN IN BEDS, WHEELCHAIRS, ARMCHAIRS AND THE LIKE.
TH96408B (en) Connection device